Research
Hormonal
The Deep Reinforcement Learning (DRL) agent decreased gastrointestinal (GI) adverse events incidence by 35% and severity by 42% in simulations.
Implementing a DRL agent for dosing may significantly reduce GI side effects in patients.
StrongSupportsmedium confidence
The DRL agent decreased GI adverse events incidence and severity by 35 and 42 per cent, respectively.
Why this rating
Based on the simulation study design described in the abstract.
Source
A Deep Reinforcement Learning (DRL) Agent for Optimizing Tirzepatide Dosing Schedules to Minimize Gastrointestinal Side Effects
Kumaran. R et al. · 2026
DOI 10.1109/raeeucci67649.2026.11504461
other · n=1000
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →